Micro-Cap Biotech with Value and Triple Digit Growth

Could This Be The Next Drug To Make It Big?

Dear Investor One micro-cap biologic stock is catching analysts' eyes. Not only is this stock trading cheaply compared to the industry average, but it has all the markings of both a value and growth play with revenue rising 106% in 2018 and expected to earn over $16.6 million in 2019. Overall Average Signals on Barchart is a 48% BUY.   Morningstar believes that this stock may be fairly valued at a 22% discount to its current trading price. The news was just announced on April 25th that it has obtained an exclusive license from Stanford University to manufacture and sell a novel protein, Wnt surrogate Fc, a substitute for a protein known as Wnt. The top-selling biologic in 2018 was Humira. Genentech's biologic drug Rituxan, a lucrative anti-cancer drug used in the treatment of Non-Hodgkin's lymphoma, received FDA approval in 1997[11] and it is still making big profits for Genentech. A quick look at the drug market today shows that 5 out of the top 10 drugs are now biologics. The potentially large returns are at a grasp for smaller pharma companies when bringing new prescription drugs to the market, especially a company like this. With this type of massive potential, this is a stock that deserves a look. See the full report and watch the exclusive CEO interview now.

This is a paid advertisement provided to customers/subscribers to DailyMarketAlerts. Although we have sent you this email, DailyMarketAlerts does NOT specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.


DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that DailyMarketAlerts is being paid on a cost-per-click basis which may exceed a fee of $1,000.00 in cash, from a third party as compensation for the distribution of this advertisement. DailyMarketAlerts has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely upon. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.